CIK 0001759138 · Non-accelerated filer<br>Smaller reporting company
Cabaletta Bio, Inc.
Sign in to watch- Ticker
- CABA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 759-3100
- Business address
- 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-09 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2026-06-09 | Simon Mark Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2026-06-09 | HENRIQUES RICHARD C JR Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2026-06-09 | Bollard Catherine Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2026-06-09 | Brun Scott C. Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2026-03-02 | Das Arun Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2026-03-02 | Gerard Michael General Counsel | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2026-03-02 | Binder Gwendolyn President, Science & Tech. | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-03-02 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-03-02 | Nichtberger Steven President & CEO | Grant or award · Stock Option (Right to Buy) | +674,000 | 674,000 | ||
| 2026-03-02 | Marda Anup Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-01-21 | Chang David J. Chief Medical Officer | Purchase | +8,800 | $2.26 | $20K | 8,800 |
| 2026-01-21 | Binder Gwendolyn President, Science & Tech. | Purchase | +11,312 | $2.19 | $25K | 31,312 |
| 2026-01-21 | Tomasello Shawn Director | Purchase | +22,725 | $2.21 | $50K | 22,725 |
| 2026-01-21 | Gavel Steve Chief Commercial Officer | Purchase | +22,170 | $2.27 | $50K | 22,170 |
| 2026-01-21 | Bollard Catherine Director | Purchase | +4,405 | $2.27 | $10K | 5,405 |
| 2026-01-21 | Nichtberger Steven President & CEO | Purchase | +45,000 | $2.24 | $101K | 1,031,483 |
| 2026-01-21 | Simon Mark Director | Purchase | +11,061 | $2.28 | $25K | 147,205 |
| 2026-01-21 | Gerard Michael General Counsel | Purchase | +6,600 | $2.27 | $15K | 6,600 |
| 2025-10-13 | Gavel Steve CHIEF COMMERCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 |
Page 1 of 13 · 256 trades